Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Moderna : CureVac founder withdraws candidacy for supervisory board

06/23/2021 | 08:23am EDT

German biotech company CureVac said Wednesday that its founder has withdrawn his candidacy for the supervisory board for health reasons.

Dr. Ingmar Hoerr, one of the leading scientists in the development of mRNA technology, was the company’s founding chief executive and later chairman. He suffered a serious stroke in March 2020.

CureVac said that Hoerr “has stated continuing health problems, which do not allow him to resume his duties.”

The company announced disappointing interim results for its coronavirus vaccine earlier this month and the future of the mRNA-based shot is unclear.

Similar technology is used by rivals Moderna and Pfizer-BioNTech in vaccines that have been widely authorized for use against COVID-19.

© 2021 The Canadian Press. All rights reserved., source Canadian Press DataFile

All news about MODERNA, INC.
02:52aSINOVAC BIOTECH : Antibodies from Sinovac's COVID-19 shot fade after about 6 mon..
RE
02:22aDassault Systemes lifts 2021 outlook on surging software sales
RE
02:21aSupply issues to delay Moderna COVID-19 vaccine shipments, S.Korea says
RE
01:37aS.korea says moderna reported that other countries receiving supply from lonz..
RE
01:28aModerna reported s.korea of problems in its vaccine manufacturing process -s...
RE
01:20aMODERNA : pushes back July vaccine shipment for S.Korea to Aug
RE
01:20aModerna pushes back july vaccine shipment schedule for s.korea to aug -s.kore..
RE
12:38aS.Korea begins COVID-19 vaccination for chip, electronics workers
RE
07/26MODERNA : Ontario asks Ottawa to work with WHO on ensuring mixed vaccines recogn..
AQ
07/26MODERNA : U.S. administers 342.2 mln doses of COVID-19 vaccines - CDC
RE
More news
Financials (USD)
Sales 2021 19 117 M - -
Net income 2021 10 725 M - -
Net cash 2021 11 948 M - -
P/E ratio 2021 13,3x
Yield 2021 -
Capitalization 140 B 140 B -
EV / Sales 2021 6,70x
EV / Sales 2022 7,51x
Nbr of Employees 1 300
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MRNA | US60770K1079 | MarketScreener
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 335,87 $
Average target price 179,20 $
Spread / Average Target -46,6%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
David W. Meline Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.221.50%140 065
LONZA GROUP AG24.05%53 538
IQVIA HOLDINGS INC.38.02%47 022
CELLTRION, INC.-26.46%32 170
SEAGEN INC.-18.34%28 525
HANGZHOU TIGERMED CONSULTING CO., LTD-5.39%25 482